(NASDAQ:ARVN), who have seen the share price tank a massive 86% over a three year period. That might cause some serious doubts about the merits of the initial decision to buy the stock, to put it ...

This stock is one of several featured in our latest research. For more small-cap opportunities with asymmetric return ...

Because Arvinas made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Shareholders of unprofitable companies usually ...

This represents a potential first for preclinical evidence of anti-tumor activity by an efficacious BCL6-targeted small-molecule degrader in a human nTFHL-AI model. Furthermore, ARV-393 monotherapy ...

The outperformance of Arvinas can be attributed to positive findings from a phase 1 study of its treatment for breast and prostate cancer. ARVN stock is also up 6x from levels of $13 seen in early ...

Arvinas believes the differentiated pharmacology of ARV-471, including its iterative degradation activity, has the potential to translate into meaningful clinical benefit for patients.

Arvinas-stock News for Arvinas Potential of Arvinas’ PROTAC® AR Degraders Reinforced by 11.1 months rPFS with Bavdegalutamide and Updated Positive Interim Data from Second Generation ARV-766 in ...

The stock price of Arvinas (NASDAQ: ARVN), a biopharmaceuticals company focused on oncology treatments based on targeted protein degradation, has fallen 24% in a month, while it’s down a ...

We recently compiled a list of the 10 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds. In this article, we are going to take a look at where Arvinas, Inc. (NASDAQ ...

Arvinas' PROTAC approach has several advantages over conventional drugs, including the potential to target "undruggable" proteins, achieve tissue-specific targeting, and cross the blood-brain barrier.

--Arvinas, Inc., a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced it presented new preclinical data from its ...